<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510378</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-072</org_study_id>
    <nct_id>NCT02510378</nct_id>
  </id_info>
  <brief_title>Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases</brief_title>
  <official_title>Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with rectal cancer and resectable liver metastases receive short course
      radiotherapy(5Gy/f x 5f) to the pelvis and XELOX consolidating chemotherapy al least 4 cycles
      after 2 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5
      Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target
      therapy) al least 4 cycles after 2 weeks.

      After evaluation, patients with resectable rectal cancer and liver metastasis will undergo
      surgery. Those patients with unresectable lesions will receive chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients undergo R0 surgery during the follow-up</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Stage IV Rectal Cancer, Liver Metastasis, Resectable</condition>
  <arm_group>
    <arm_group_label>Short course radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.
After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short course radiotherapy</intervention_name>
    <description>Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.
After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy.</description>
    <arm_group_label>Short course radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed primary carcinoma of the rectum (Lower border of tumour â‰¤ 10
             cm from anal verge) locally advanced stage in primary site of rectum resectable
             synchronous liver metastases. The decision of resectable liver metastases will be made
             at multidisciplinary clinical meetings.

        Exclusion Criteria:

          -  Obstruction of the gastrointestinal tract Previously constructed stoma prior
             radiotherapy of the pelvis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hua Ren</last_name>
    <phone>8610-87788122</phone>
    <email>renhua2009@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Jin, chairman</last_name>
    <phone>8610-87788122</phone>
    <email>jingjin1025@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Radiation oncology, Cancer Hospital , Chinese Academy of Medical Science</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jing jin</last_name>
      <phone>8610-87788280</phone>
      <email>jingjin1025@163.com</email>
    </contact>
    <contact_backup>
      <last_name>hua ren</last_name>
      <phone>8610-87788122</phone>
      <email>renhua2009@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>jing jin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, CAMS</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Jin, professor</last_name>
      <phone>87788200</phone>
      <email>jingjin1025@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hua Ren, attending</last_name>
      <phone>87788122</phone>
      <email>renhua2009@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Hua Ren</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

